Header

UZH-Logo

Maintenance Infos

Therapeutic options in recurrent glioblastoma-An update


Seystahl, Katharina; Wick, Wolfgang; Weller, Michael (2016). Therapeutic options in recurrent glioblastoma-An update. Critical Reviews in Oncology/Hematology, 99:389-408.

Abstract

INTRODUCTION
Standards of care are not yet defined in recurrent glioblastoma.

METHODS
We reviewed the literature on clinical trials for recurrent glioblastoma available in PubMed and American Society of Clinical Oncology (ASCO) abstracts until June 2015.

RESULTS
Evidence is limited due to the paucity of randomized controlled studies. Second surgery or re-irradiation are options for selected patients. Alkylating chemotherapy such as nitrosoureas or temozolomide and the vascular endothelial growth factor (VEGF) antibody, bevacizumab, exhibit comparable single agent activity. Phase III data exploring the benefit of combining bevacizumab and lomustine are emerging. Novel approaches in the fields of targeted therapy, immunotherapy, and tumor metabolism are coming forward. Several biomarkers are being explored, but, except for O(6)-methylguanine DNA methyltransferase (MGMT) promoter methylation, none has assumed a role in clinical practice.

CONCLUSION
Proper patient selection, development of predictive biomarkers and randomized controlled studies are required to develop evidence-based concepts for recurrent glioblastoma.

Abstract

INTRODUCTION
Standards of care are not yet defined in recurrent glioblastoma.

METHODS
We reviewed the literature on clinical trials for recurrent glioblastoma available in PubMed and American Society of Clinical Oncology (ASCO) abstracts until June 2015.

RESULTS
Evidence is limited due to the paucity of randomized controlled studies. Second surgery or re-irradiation are options for selected patients. Alkylating chemotherapy such as nitrosoureas or temozolomide and the vascular endothelial growth factor (VEGF) antibody, bevacizumab, exhibit comparable single agent activity. Phase III data exploring the benefit of combining bevacizumab and lomustine are emerging. Novel approaches in the fields of targeted therapy, immunotherapy, and tumor metabolism are coming forward. Several biomarkers are being explored, but, except for O(6)-methylguanine DNA methyltransferase (MGMT) promoter methylation, none has assumed a role in clinical practice.

CONCLUSION
Proper patient selection, development of predictive biomarkers and randomized controlled studies are required to develop evidence-based concepts for recurrent glioblastoma.

Statistics

Citations

Dimensions.ai Metrics
32 citations in Web of Science®
36 citations in Scopus®
33 citations in Microsoft Academic
Google Scholar™

Altmetrics

Downloads

117 downloads since deposited on 07 Jun 2016
110 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, further contribution
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Neurology
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:March 2016
Deposited On:07 Jun 2016 07:40
Last Modified:02 Feb 2018 10:02
Publisher:Elsevier
ISSN:1040-8428
OA Status:Green
Publisher DOI:https://doi.org/10.1016/j.critrevonc.2016.01.018
PubMed ID:26830009

Download

Download PDF  'Therapeutic options in recurrent glioblastoma-An update'.
Preview
Content: Accepted Version
Filetype: PDF
Size: 376kB
View at publisher
Licence: Creative Commons: Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)